eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis

Company Overview

eFFECTOR Therapeutics, Inc. was a clinical-stage biopharmaceutical company focused on developing medicines that target the process of protein translation, an area of biology involved in cancer growth and immune regulation. The company’s approach was designed to selectively disrupt translation pathways that tumors depend on while potentially limiting effects on healthy cells.

Its lead investigational program was zotatifin (eFT226), an oral small-molecule inhibitor of eIF4A, a protein involved in the translation of certain cancer-promoting messenger RNAs. eFFECTOR evaluated zotatifin in clinical studies for advanced solid tumors, including in combination with other anticancer therapies. The company also developed earlier translation-regulation programs, including tomivosertib (eFT508), an investigational inhibitor of MNK1 and MNK2 intended to influence production of proteins involved in tumor development and immune response.

eFFECTOR was founded in 2012 and was headquartered in San Diego, California. It operated primarily as a research and development organization serving the oncology market through collaborations and clinical development activities. Publicly available company materials have identified co-founder and Chief Executive Officer Steve Worland as a member of its leadership team; the company’s corporate status and leadership may have changed as its development activities evolved.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.02
• Volume: N/A
• Average Volume: 6,297 shs
• Market Capitalization: $940.80
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/08/2021
• Today: 10/05/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:EFTR
• CIK: 1828522
• Web: effector.com
• Phone: 858-925-8215
• Fax: N/A
• Employees: 14
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.94) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 4,704,000
• Free Float: 4,483,000
• Market Cap: $940.80
• Optionable: No Data
• Beta: 2.73